Are failure prone x-ray crystallography and cryoEM straining your budget? Get structural verification of your antibody binding sites in just weeks – non-linear epitopes and tough targets included. Our milestoned project approach means each project is de-risked – no more expenses for failed attempts!
You’ll get:
A concise introduction to modern epitope mapping
A look at the current techniques used to perform epitope mapping
Actionable summaries of protein footprinting for epitope mapping
A case study demonstrating a cutting-edge technique in practice
When you think of small molecule drugs, you think of the binding site, or a “lock-and-key" analogy– similarly, no biologic is complete without fully characterizing and understanding its epitope, or binding site - it’s a must have. Before you settle for a suboptimal approach, give our epitope mapping platform a try. Our technique, epitope mapping by hydroxyl radical protein footprinting (HRPF), circumvents all of the major drawbacks of current approaches — it’s ultra-fast, universally compatible, works in native conditions, and all of our projects are guaranteed.
Common epitope mapping techniques, like x-ray crystallography and cryoEM, are prone to failure, prohibitively expensive, and incompatible with certain classes of targets (e.g. integral membrane proteins and megacomplexes). Other approaches developed to circumvent these issues, like mutagenesis, peptide scanning, and hydrogen-deuterium exchange mass spectrometry, expose the target to non-native conditions, miss non-linear and non-obvious epitopes, and can be unreliable and unreproducible. So what’s a developer to do?
In this paper, we provide a clear and concise introduction our approach for epitope mapping, explore its essential role in drug development, and explain, with evidence, how we analyze proteins in a fraction of the time and at a fraction of the cost and complexity compared to traditional techniques.
Mapping the binding sites (or epitopes) of antibodies and their target antigens is critical for understanding their mechanism of action as well as filing patent claims. In addition, understanding the motion and dynamics of the antigen in response to binding provides additional insight to advance therapeutic candidates and maximize efficacy.
Epitope mapping is often relegated to the later stages of discovery because of the challenges with capturing the structural detail of the antibody/antigen interaction. There is one clear cause: the techniques that are commonly used for epitope mapping, including x-ray crystallography, peptide scanning, mutagenesis, and hydrogen-deuterium exchange (HDX), all have significant limitations and drawbacks.
Our orthogonal technique for protein footprinting is called hydroxyl radical protein footprinting - we use our proprietary platform to label proteins and detect changes in solvent accessibility of protein side chains. Top pharmaceutical companies and biotechnology firms are working with Immuto and deploying epitope mapping by HRPF to condense the discovery process and curtail the millions of dollars spent on discovery.
This paper provides ample information and evidence to understand our approach, provides hard data and case studies so you can evaluate its utility, details where it can be applied, and describes how it will give your organization an advantage in streamlining drug discovery and development.
Submit the form below and we'll send the white paper right to your inbox.
This paper covers the basics of epitope mapping, summarizes the latest published research into its functions and utility, and provides a practical look at how our approach is poised to give a significant competitive advantage at the earliest stages of the development lifecycle.
It's essential reading for anyone involved in therapeutic R&D looking to bring efficiency, depth of insight, and temporal and economic savings to their discovery processes. Ensure that you stay informed of new technologies and techniques for streamlining discovery and development.
Get a practical, applied look at epitope mapping in biologic drug development.
See why epitope mapping is important for antibody discovery.
Explore the current techniques: Hydrogen Deuterium eXchange and Hydroxyl Radical Protein Footprinting
See the benefits of using PLIMB for HRF.
We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.
